Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05283720
Title A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Epcoritamab + Lenalidomide

Epcoritamab + Ibrutinib + Lenalidomide

Cyclophosphamide + Doxorubicin + Epcoritamab + Polatuzumab vedotin-piiq + Prednisone + Rituximab

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN


No variant requirements are available.